This June planet-top cancer researchers from about the globe are receiving prepared to present and talk about the most up-to-date advances in the oncology at the 2023 ASCO Annual meeting in Chicago. Ahead of the meeting, we appear at some of the ICR’s investigation getting presented this year.
Posted on 01 June, 2023
by Julia Bakker
From two-six June several scientists from The Institute of Cancer Investigation, London, will join a worldwide forum of planet-top scientists and oncologists at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
A worldwide highlight of the cancer investigation calendar, ASCO sees the most up-to-date, practice-altering benefits from key phase III trials presented alongside fascinating early phase trial benefits, translational investigation, and insightful commentary on all elements of oncology.
This year’s theme is Partnering with Sufferers: The Cornerstone of Cancer Care and Research and the meeting will concentrate on improved, far more equitable cancer care, and the significance of meaningful relationships amongst oncologists and individuals.
Retain reading for a summary of research getting presented by researchers from the ICR and our partners The Royal Marsden NHS Foundation Trust at ASCO 2023.
To access the complete programme with certain timings and areas take a look at the ASCO internet site.
Friday two June
- Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER optimistic and HER2 unfavorable breast cancer: Evaluation from the PENELOPE-B trial.
Oral abstract quantity: 502
Saturday three June
- A phase (Ph) I/II trial of abiraterone acetate in mixture with tildrakizumab (anti-IL23 monoclonal antibody) in individuals with metastatic castration-resistant prostate cancer (mCRPC).
Poster Bd #: 195b
- Lisavanbulin in individuals with recurrent glioblastoma: Phase 2a benefits and a consolidated evaluation of response-predictive biomarkers.
Poster Bd #: 401
- Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in individuals with metastatic soft-tissue sarcomas (mSTS).
Shane H Zaidi,
Poster Bd #: 486
- The Man Van: Mobile targeted case locating for prostate cancer
Poster Bd #: 14
- CONSENT: Randomized controlled trial of enhanced informed consent compared to regular informed
Poster Bd #: 52
- General survival and extended-term security in individuals with sophisticated gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
Poster Bd #: 458
Sunday four June
- Subcutaneous amivantamab (ami) in individuals (pts) with sophisticated strong malignancies: The PALOMA study—Updated security and identification of the advised phase two dose.
Poster Bd #: 114
- Randomised open-label phase II study of induction regular of care fulvestrant and CDK4/six inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer individuals with out circulating tumour (ct) DNA suppression (FAIM).
Alicia Frances Clare Okines
| Poster Bd #: 332a
Monday five June
- Jumping Ahead, Falling Behind, or Standing Nevertheless in the Frontline Setting for Sophisticated Melanoma?
- State-of-the-Art Management of Biliary Tract Cancers – The Healthcare Oncologist’s Point of view
- A phase two, open-label, multicenter study investigating efficacy and security of RP3 oncolytic immunotherapy combined with other therapies in individuals with locoregionally sophisticated or recurrent squamous cell carcinoma of the head and neck.
Poster Bd #: 95b
- Prognostic things of early mortality in young children and adolescents enrolled in oncology trials with a dose-locating portion in the era of targeted and immune therapies: An Revolutionary Therapies for Youngsters with Cancer (ITCC) study
Poster Bd #: 326
- Initial efficacy and security benefits from ENGOT-ov60/GOG-3052/RAMP 201: A phase two study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Poster Bd #: 210
Join the conversation on social media with the hashtag #ASCO2023.
Study far more news and stories from the ASCO Annual Meeting.
ASCO Annual Meeting
comments powered by